(Q39986134)

16 September 2017

title

Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene (English)

1 reference

16 September 2017

1 reference

Kang Yu

1

1 reference

16 September 2017

Yongxian Hu

2

1 reference

16 September 2017

Yinxia Tan

3

1 reference

16 September 2017

Zhijian Shen

4

1 reference

16 September 2017

Songfu Jiang

5

1 reference

16 September 2017

Honglan Qian

6

1 reference

16 September 2017

Bin Liang

7

1 reference

16 September 2017

Daming Shan

8

1 reference

16 September 2017

publication date

1 July 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

49

1 reference

16 September 2017

issue

7

1 reference

16 September 2017

page(s)

1368-1373

1 reference

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802064958

10.1080/10428190802064958

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference